Topiramate Tablet
Product Images NDC 51655-606

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 51655-606). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 606 26 Master Bottle Label Approval Rev A 05 20)

This is a description of a medication package containing 90 film-coated tablets of Topiramate USP, 50 mg each. The tablets are stored in an original container and must be kept at a temperature range of 20°C to 25°C to protect them from moisture. The package has a National Drug Code (NDC) of 51655-606-26 and a lot number of 0000000000. This medicine is only available with a prescription because it is labeled as Rx Only. The dosage is specified on the package insert. The package was repackaged by Northwind Pharmaceuticals from a package with NDC 69097-123-15 manufactured by Cipla USA, Inc. The other details are not available due to errors.*

FDA Label Image

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01)

FDA Label Image

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02)

This appears to be a graph or chart displaying the cumulative rates for time to the first seizure among participants taking different doses of topiramate. The x-axis shows time in days and the y-axis shows the cumulative rate. The two lines on the graph represent two different doses of topiramate (50mg/day and 400mg/day), with the higher dose appearing to have a slightly faster time to first seizure.*

FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency(studies 10 And 11 For Adults And Adolescents) (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03)

The text describes the change in the average monthly migraine period rate in a double-blind study after taking either 100 or 200 milligrams per day of Topamax medication. The text includes statistical significance levels denoted by asterisks, however, there is incomplete information to interpret the result.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.